FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
Luminice-203 yields its first topline data, but where are all the patients?
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.
Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.